Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 11, 2012, Pages 2303-2309

  Liu, C ^a,b   Kawedia, J D ^a   Cheng, C ^c   Pei, D ^d   Fernandez, C A ^a   Cai, X ^a   Crews, K R ^a   Kaste, S C ^b,d   Panetta, J C ^a   Bowman, W P ^e   Jeha, S ^a   Sandlund, J T ^a   Evans, W E ^a   Pui, C H ^a   Relling, M V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Departments of Biostatistics   (United States)

^d Departments of Radiological Sciences   (United States)

^e Cook Childrens Hospital ^*  (United States)

Author keywords

Allergy; Antibody; Asparaginase; Osteonecrosis; Pharmacodynamics

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BONE NECROSIS; CHILD; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; THROMBOSIS;

ANTIBODIES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84869079214     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.102     Document Type: Article

References (41)

1. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: Clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893-901.
2. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315: 657-663. (Pubitemid 16055930)
3. Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989; 49: 4363-4368. (Pubitemid 19207288)
4. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615. (Pubitemid 28385659)
5. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M et al. Intensive highdose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999; 13: 335-342. (Pubitemid 29108071)
6. Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallai L, Tan CC et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25: 253-278.
7. Peterson RG, Handschumacher RE, Mitchell MS. Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080-1090.
8. KillanDer D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220-228.
9. Evans WE, Tsiatis A, Rivera G, Murphy SB, Dahl GV, Denison M et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982; 49: 1378-1383. (Pubitemid 12143059)
10. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986; 8: 99-104. (Pubitemid 16092149)
11. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-1533. (Pubitemid 28470435)
12. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002; 99: 1986-1994. (Pubitemid 34525479)
13. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26: 217-226. (Pubitemid 38500969)
14. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525-1532. (Pubitemid 30205399)
15. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12: 660-665. (Pubitemid 28220817)
16. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007; 48: 931-936.
17. Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: A Children's Oncology Group Study. J Pediatr Hematol Oncol 2007; 29: 627-632. (Pubitemid 47368000)
18. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 199-205.
19. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
20. Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011; 43: 237-241.
21. Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 2010; 88: 191-196.
22. Wang B, Hak LJ, Relling MV, Pui CH, Woo MH, Storm MC. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000; 239: 75-83. (Pubitemid 30256020)
23. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786. (Pubitemid 23277332)
24. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011; 117: 2340-2347quiz 2556.
25. Therneau T, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer-Verlag: New York, 2000.
26. Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008; 26: 1932-1939.
27. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: A systematic review. Ann Intern Med 2004; 140: 589-602.
28. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808. (Pubitemid 351650500)
29. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum 2002; 47: 434-444. (Pubitemid 34856134)
30. Willer A, Gerss J, Konig T, Franke D, Kuhnel HJ, Henze G et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: A retrospective analysis within the ALL-BFM trials. Blood 2011; 118: 5774-5782.
31. Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22: 3930-3936. (Pubitemid 41079875)
32. Sala A, Mattano Jr. LA, Barr RD. Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. Eur J Cancer 2007; 43: 683-689. (Pubitemid 46502899)
33. Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M. Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005; 44: 220-225. (Pubitemid 40209430)
34. Mattano Jr. LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 2000; 18: 3262-3272.
35. Yang L, Boyd K, Kaste SC, Kamdem Kamdem L, Rahija RJ, Relling MV. A mouse model for glucocorticoid-induced osteonecrosis: Effect of a steroid holiday. J Orthop Res 2009; 27: 169-175.
36. Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997; 89: 1886-1895. (Pubitemid 27132102)
37. Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 1998; 83: 379-384. (Pubitemid 28317820)
38. Hanada T, Horigome Y, Inudoh M, Takita H. Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy. Eur J Pediatr 1989; 149: 162-163. (Pubitemid 20015178)
39. te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica 2008; 93: 1570-1574.
40. Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2012; 119: 1658-1664.
41. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17: 1583-1588. (Pubitemid 36992159)